Skip to content

Promoter-Targeted CRISPR Correction of PMP22 Gene Dosage Restores Schwann Cell Homeostasis in Charcot-Marie-Tooth Disease Type 1A.

Sep 2026 · Tissue Engineering and Regenerative Medicine · 0 citations · 34 references
Medicine

TL;DR

Collectively, patient-anchored, promoter-targeted genome editing can potentially correct pathogenic PMP22 dosage while preserving basal expression, establishing a translational iPSC-based framework for treating dosage-sensitive demyelinating neuropathies such as CMT1A.

View source

Similar papers

#gene editing Review Open access Oct 2026

The genetic architecture and pharmacogenetic landscape of Charcot-Marie-tooth disease type 1 A: a narrative review toward precision molecular therapeutics

Current evidence on the genetic, molecular, and regulatory architecture of CMT1A is synthesized, with particular emphasis on distal regulatory elements controlling PMP22 expression, promoter-specific transcriptional regulation, and mechanisms contributing to phenotypic heterogeneity, support an increasingly individuali...

Yousef VatanParast · 0 citations
Open access Aug 2026

Advanced iPSC-based modelling of LMNA-related congenital muscular dystrophy enables development of genetic therapies for muscle laminopathies.

The selection of L-CMD iPSCs is expanded, disease-associated readouts are validated using a transgene-free differentiation protocol and gene editing strategies are assessed using 2D and 3D cultures, providing an advanced, humanised platform for translational research and precision medicine in laminopathies.

D. Moore, H. Steele-Stallard, Luca Pinton et al. · 0 citations
Open access Sep 2026

Evaluating the pathogenic significance of unique chromosomal variants in craniosynostosis using patient-derived induced pluripotent stem cells and mouse modelling.

Patient iPSC-differentiated NCC and OPC lines, combined with TAD-based modelling to generate testable functional hypotheses, provide valuable functional evidence when evaluating causation of unique SV/CNV in craniosynostosis.

D. Korona, Akiko Hashimoto, Yang Pei et al. · 0 citations
Open access Oct 2026

CRISPR/Cas9‐Mediated Correction of the SLC25A38 Mutation in a Patient With Sideroblastic Anemia

ABSTRACT Background The SLC25A38 is one of the genes of the heme biosynthesis pathway and disruptive alterations therein cause autosomal recessive congenital sideroblastic anemia (CSA). Primary patient‐derived fibroblasts can be used as a valuable source for disease modeling, cell therapy studies, and the generation of...

S. Yazdanparast, H. Galehdari, S. Khatami et al. · 0 citations
#gene editing Open access Sep 2026

Mutation-specific correction of SOD1 in familial ALS using prime and base editing in human induced pluripotent stem cells

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration and respiratory failure. Approximately 10% of ALS cases are familial, with mutations in SOD1 representing a major genetic cause. Preservation of physiological SOD1 function may be i...

K. Imamura, Kayoko Tsukita, Shin Yoshioka et al. · 0 citations
Sep 2026

Gene-Corrected Human iPSC-Derived Cardiomyocytes and Skeletal Muscles Reveal Partial Dystrophin Dp427 Preservation and Cardiac Dp116 Expression in Duchenne Muscular Dystrophy Patient With a Splice-Site Mutation in Intron 68 (c.9975-1G>T).

BACKGROUND Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disease caused by mutations in the DMD gene, leading to the absence or dysfunction of dystrophin. Although cardiac and skeletal muscles are both affected, tissue-specific differences in disease manifestation and dystrophin regulation remain...

M. Białobrzeska, M. Przymuszała, Paweł E. Ferdek et al. · 0 citations

Related blog posts

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.